Aurobindo Pharma Ltd. News and Updates

Name: Latest research reports of Aurobindo Pharma Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 4
Author: Prabhudas Lilladhar

Keep track of all breaking news on Aurobindo Pharma Ltd. from all sources in a single place.

Load latest

Aurobindo Pharma Ltd.

16 Feb 2021, 12:00AM

1091.60

-0.77%

Monthly Update - IPM grapple for normalized growth after COVID

Accumulate: Aurobindo Pharma Ltd.

Prabhudas Lilladhar

IPM is struggling for growth above 10% even after MoM abating COVID concerns and with MRs, physician activities almost reaching pre-COVID level. We believe key reasons for growth below par are (i) subdued new prescription (Rx) leading to volume de-growth (ii) digital marketing yield going south and (iii) sustained lower demand of acute products. Cardiac and anti-diabetic growth takes a breather in Jan-21 at 8.8% and 5.3% after reporting double digit growth in most months during lockdown. While amongst top therapies Gastro and VMN reported double digit growth of 14%...

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1129.3

Aurobindo Pharma Ltd.

15 Feb 2021, 06:59PM

1091.60

-0.77%

Buy Aurobindo Pharma; target of Rs 1165: ICICI Direct

Moneycontrol

ICICI Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1165 in its research report dated February 11, 2021.

Aurobindo Pharma Ltd. has lost -30.35% in the last 1 Year

Aurobindo Pharma Ltd.

15 Feb 2021

1091.60

-0.77%

AUROBINDO PHARMA LTD

Buy: Aurobindo Pharma Ltd.

Target

Geojit BNP Paribas

EBITDA grew 13.3% YoY, EBITDA margin expanded 100bps to 21.5% mainly due to increased gross margin (+60bps YoY), and partially offset by higher R&D; spends. Net profit surged 4x YoY, on account of...

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1129.3

Aurobindo Pharma Ltd.

12 Feb 2021

1091.60

-0.77%

Covid-19: Aurobindo Pharma working on multiple' vaccines

Business Line

Drug-maker to double production capacity to 480 million doses by 2021

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma steady as analysts watch numbers for near-term growth

Business Standard | 12 Feb 2021 1 more

Aurobindo Pharma Ltd.

12 Feb 2021

1091.60

-0.77%

Result Update:Aurobindo Pharma

Buy: Aurobindo Pharma Ltd.

Target

Axis Direct

We expect revenue and PAT CAGR of 9.6% and 13.9% over the period FY20-FY23E and recommend Buy with TP of Rs 1,030.

Aurobindo Pharma Ltd. has lost -30.35% in the last 1 Year

Aurobindo Pharma Ltd.

11 Feb 2021

1091.60

-0.77%

Aurobindo Pharm Standalone December 2020 Net Sales at Rs 3,710.86 crore, up 10.92% Y-o-Y

Moneycontrol

NULL

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1129.3

Aurobindo Pharm Consolidated December 2020 Net Sales at Rs 6,364.91 crore, up 7.97% Y-o-Y

Moneycontrol | 11 Feb 2021 3 more

Aurobindo Pharma Ltd.

11 Feb 2021

1091.60

-0.77%

Q3FY21 Result Update - Product mix to shift towards injectable and specialty; Upgrade to Accumulate

Accumulate: Aurobindo Pharma Ltd.

Target

Prabhudas Lilladhar

CAPA completed for Unit-I, IX, VII and XI. Awaiting USFDA inspection. We upgrade ARBP rating to Accumulate (earlier Hold) as we increase the multiple assigned on FY23E to 15x (PE) v/s earlier 13x. This multiple re-rating...

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1129.3

Aurobindo Pharma Ltd.

11 Feb 2021

1091.60

-0.77%

Aurobindo Pharma Limited

Buy: Aurobindo Pharma Ltd.

Target

ICICI Securities Limited

Adjusting for certain one-off exceptional items, Q3 results were in line with I-direct estimates on all fronts. Aurobindo has one of the most enduring generics ecosystems among peers (vertically integrated model, lower product concentration) to withstand volatility in the US and other generics space. It has also significantly improved its net debt position from foregoing the Sandoz deal and from the recent sale of Natrol business. This also bodes well as the company plans to venture into complex areas like biosimilars, vaccines and complex injectables where capital requirements are higher and...

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1090.5

Aurobindo Pharma Ltd.

25 Jan 2021

1091.60

-0.77%

Aurobindo Pharma's scrip zooms 8%

Business Line

Shares of Aurobindo Pharma surged 8 per cent on the BSE on Monday to 998 on incentive booster. The company's project for production of penicillin G h

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.

Aurobindo Pharma hits 52-week high on approval under PLI

Business Line | 25 Jan 2021 1 more

Aurobindo Pharma Ltd.

22 Jan 2021

1091.60

-0.77%

Aurobindo, Kinvan, K'taka Antibiotics first to get PLI for drugs

Business Today

While Aurobindo Pharma has committed an investment of Rs 3,039 crore to set up production facilities for three eligible products, Kinvan will invest Rs 447.17 crore to build 300 MT capacity plant to produce Clavulanic Acid